About Me
I am a urologist specializing in urologic oncology. I obtained my medical training at Northwestern University in Chicago and completed my surgical residency in urology at Johns Hopkins University in Baltimore. Subsequently, I completed a fellowship in urologic oncology at the University of Texas MD Anderson Cancer Center.
Treatment for urologic cancers can include multiple treatment choices, and I enjoy getting to know my patients and their priorities to determine the best care plans for each individual patient.
As a member of the Cancer Biology Program at the OSUCCC – James, my research focuses on exploring the functions of immune suppressive cells in the bladder cancer tumor microenvironment (in particular, myeloid derived suppressor cells) and identifying and blocking MDSC-specific signaling pathways. In so doin, my aim is to overcome therapeutic resistance to immune checkpoint blockade, which is a pressing clinical issue in bladder cancer. I am also exploring the use of beta-catenin inhibitors to modulate the tumor immune microenvironment and studying determinants of bladder cancer chemosensitivity.
In addition to performing research, which has been published in numerous peer-reviewed journals, I also serve as an editor for BMC Cancer and a reviewer for European Urology, Urologic Oncology, Journal of Urology and PLoS ONE. While I was at Johns Hopkins, I received the Frank L. Coulson, Jr., Award for Clinical Excellence, and my research in prostate cancer was recognized by ASCO in 2013 as one of the Clinical Cancer Advances of the year. While I was at MD Anderson, I received the Conquer Cancer Foundation of ASCO Merit Award and the William L. Pippin Endowed Fellowship for my work in bladder cancer research.
The OSUCCC – James is an incredible place. A direct benefit of the cutting-edge research and technology here is that I can offer my patients state-of-the-art treatment strategies and surgical options that maximize safety and precision. I am proud to be a member of The James, and to be part of the process that lifts oncology care to such heights is a true honor.
Procedures and Conditions I Treat
- Minimally Invasive Surgical Procedures
- Robotics
- Bladder Cancer
- Kidney Cancers
- Prostate Cancers
- Testicular Cancers
- Urethral Cancers
- Hematuria
- Adrenal Gland Cancers
- Urology
Education and Training
Education History
Medical School
Northwestern University Feinberg School of Medicine, Chicago, IL
8/1/2004 - 5/20/2009
Internship
Johns Hopkins Hospital, Baltimore, MD
7/1/2009 - 6/30/2010
Residency
Johns Hopkins Hospital, Baltimore, MD
7/1/2010 - 6/30/2015
Fellowship
University of Texas MD Anderson Cancer Center, Houston, TX
7/1/2015 - 6/30/2017
Board Certification
American Board of Urology
2/28/2019
Academic Information
My Department
Urology
My Division
Urology
Consulting and Related Relationships
At The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the University requires annual disclosures from all faculty members with external interests related to their University responsibilities.
As of 09/30/2024, Dr. Sundi has reported no relationships with companies or entities.
